RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Arcus Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.14+0.02 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Arcus Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other collaboration | $25.00M | $5.00M | $4.00M | $6.00M | $8.00M | $8.00M | $8.00M | $7.00M | $11.00M | $10.00M | $9.00M | $10.00M | 61.0% | +212.5% |
| License and development services | $16.00M | $12.00M | – | – | $152.00M | $20.00M | – | – | – | – | – | – | 39.0% | -89.5% |
| License and Development Services Revenue | – | – | – | $20.00M | $152.00M | $20.00M | $18.00M | $41.00M | $28.00M | $135.00M | $22.00M | $22.00M | – | – |
| Access rights | – | – | – | – | – | – | – | – | $9.00M | $8.00M | $8.00M | $8.00M | – | – |
| Access rights | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| License and R&D services | – | – | – | – | – | – | – | – | $27.00M | $133.00M | $22.00M | $20.00M | – | – |
| R&D services | – | – | – | – | – | – | – | – | $3.00M | $4.00M | $1.00M | $4.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Arcus Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.